KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation

Bookmark and Share
Published: 20 Sep 2021
Views: 558
Rating:
Save
Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA

Dr Jared Weiss speaks to ecancer about the KRYSTAL-1 trial. He discusses adagrasib as monotherapy or combined with cetuximab in patients with colorectal cancer harbouring a KRASG12C mutation. Initially, he talks about the rationale of the study.

Dr Weiss then discusses the methodology and results. The study proves that adagrasib is well tolerated as monotherapy and combined with cetuximab. It demonstrates promising clinical activity in heavily pretreated patients with KRASG12Cmutant CRC.

He concludes by mentioning that adagrasib and cetuximab are currently being evaluated in the 2L setting in a phase 3 trial of patients with KRASG12C-mutant CRC.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.